Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2025-01-08
2025-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reproducibility of Acute Caffeine Effect
NCT06606639
Caffeine, Resistance Exercise and Muscle/Cerebral Oxygenation
NCT07001176
Caffeine, Resistance Exercise and EMG
NCT06606652
Caffeine and Resistance Training in Older Adults
NCT06618261
Acute Caffeine Ingestion on Futsal Performance
NCT04852315
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: To determine the effects of ingesting caffeine at a dose of 3 mg/kg body mass on pull-up performance and handgrip-related measures in trained climbers.
Methods: Thirteen trained young male climbers participated in a triple-blind, randomized, crossover study design, completing two experimental conditions (caffeine and placebo). Performance assessments included a pull-up one-repetition maximum (1RM), a pull-up power test conducted at multiple external loads, a pull-up endurance test, and several grip performance evaluations, namely maximal dead-hang duration, maximal dead-hang force, and rate of force development (RFD).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
0 mg/kg of caffeine
Placebo
Placebo supplementation was provide to young male climbers.
Caffeine
3 mg/kg of caffeine
Acute and moderate dose of caffeine (3 mg/kg body mass)
Caffeine supplementation was provide to young male climbers.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acute and moderate dose of caffeine (3 mg/kg body mass)
Caffeine supplementation was provide to young male climbers.
Placebo
Placebo supplementation was provide to young male climbers.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 40 years
* At least three months of continuous climbing practice
* Ability to hang for at least 5 seconds from an 18-mm edge
* Ability to perform at least one strict body-weight pull-up
Exclusion Criteria
* Participation in less than three training sessions per week or a total training volume \<150 min/week
* Use of medications or dietary supplements known to affect caffeine metabolism
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Alcala
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alberto Pérez-López
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alberto Pérez López, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Alcala
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
Alcalá de Henares, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEIP/2024/5/117
Identifier Type: OTHER
Identifier Source: secondary_id
CEIP/2024/5/117
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.